Find Clinical Trials

Inclusion Criteria: * Current diagnosis of major depressive disorder, defined as: * Positive diagnosis on the MINI diagnostic interview, and * PHQ-9 score greater than 10 * Evidence of personality dysfunction, defined as a score above the cutoff on the Level of Personality Functioning Scale-Brief Form (LPFS-BF 2.0). * History of moderate to severe early life adversity, defined as elevated scores on at least one scale of the Childhood Trauma Questionnaire (CTQ), and/or clinically significant alterations in self-organization. * Presence of at least one elevated domain of alteration of self-organization, including emotion regulation difficulties, interpersonal sensitivity, and/or interpersonal functioning problems, as assessed by standardized self-report measures (DERS, A-RSQ, OQ-45-IR). * Receiving care at a participating public community mental health center in Chile. * Ownership of a smartphone (Android or iOS) with internet access and an active data plan. * Ability to provide written informed consent. Exclusion Criteria: * Acute suicide risk requiring immediate intensive intervention, as assessed by the MINI. * Any severe psychiatric disorder other than major depressive disorder that is the primary clinical diagnosis, including: * Schizophrenia or other psychotic disorders * Bipolar I disorder * Severe substance use disorder, active within the past 6 months. * Diagnosis of post-traumatic stress disorder (PTSD) meeting full diagnostic criteria, as assessed by standardized instruments (ITEM and ITQ). * Meeting diagnostic criteria for: * Antisocial personality disorder (two or more criteria), or * Borderline personality disorder with more than three diagnostic criteria * Severe medical, cognitive, or psychosocial condition that would interfere with participation in weekly psychotherapy. * Concurrent participation in another active psychotherapy or initiation/change of psychotropic medication during the study period, except for: * Stable antidepressant treatment * Medications prescribed for sleep * Benzodiazepines used only on an as-needed (PRN) basis. * Inability to comply with study procedures or assessments.

Inclusion Criteria: * Adolescents between the ages of 12 and 17 who have been diagnosed with a major depressive disorder (mild or moderate) and/or an anxiety disorder. * Participants may have co-occurring mild to moderate alcohol or drug use problems, provided these do not require immediate specialized treatment or crisis intervention. * All participants must be receiving care at one of two participating MCHS outpatient psychiatry clinics and may reside in rural area (RUCA code 4-10) or non-rural area. * Participants must be able to read and understand English, and both parental or guardian consent and adolescent assent will be required. Exclusion Criteria: * Current suicidal ideation or self-harm behavior requiring immediate clinical intervention * Presence of severe psychiatric comorbidities such as psychosis, bipolar disorder, depression with psychotic features, severe alcohol and drug use, or eating disorders. * Participants with significant cognitive impairment that would interfere with study participation.

Inclusion Criteria: * Women aged 18 years or older. * Diagnosed with any type and stage of breast cancer. * Receiving care at Hospital Clínico San Carlos (Madrid, Spain). * Willing and able to provide informed consent. * Eligible to participate in physical activity based on clinical evaluation. Exclusion Criteria: * Medical contraindications to physical exercise. * Severe uncontrolled conditions (whether related to cancer treatment or not). * Diagnosis of recurrent breast cancer. * Refusal or inability to sign the informed consent form.

Inclusions Criteria To participate in this study, a subject must meet all the eligibility criteria outlined below. * Age ≥ 18 years at the time of consent * Able to read and speak English. * Have had surgery, such as a mastectomy or lumpectomy, to remove some or all of their breast or breasts. * Breast surgery occurred within the past 8 years. * Breast surgery was due to a diagnosis of breast cancer, ductal carcinoma in situ, or risk of future breast cancer, by participant report. * Sex was assigned "Female" at birth Exclusion Criteria • Individuals with self-reported or observed unstable medical or psychiatric conditions precluding informed consent or participation in the study will be excluded.

Inclusion Criteria: * Age: 18-80 years * Current diagnosis of major depressive disorder (MDD) according to DSM-5, confirmed by structured clinical interview (e.g., DIPS) * Hamilton Depression Rating Scale (HAMD-21) score ≥ 9 * Ability to attend group therapy sessions (2×/week for 5 weeks) * Ability to undergo MRI scanning (for participants in the fMRI component) Written informed consent Exclusion Criteria: * Current or lifetime diagnosis of bipolar disorder, psychotic disorder, or primary substance use disorder * High acute suicide risk requiring immediate intervention * Severe neurological disorder, brain injury, or contraindications for MRI (e.g., metal implants, claustrophobia) * Ongoing psychotherapy or initiation of a new antidepressant medication within the past 4 weeks * Insufficient German language proficiency to participate in therapy and complete study assessments * Cognitive impairment or other conditions interfering with informed consent or study participation

Inclusion Criteria: * Pregnant women in their first and second trimesters. * Aged 18 years and older. * Able to read and understand Chinese * Own a smartphone with iOS or Android system. Exclusion Criteria: * Psychiatric diagnosis (e.g., schizophrenia, intellectual disability or mood disorders), comorbid brain conditions (history of epilepsy, stroke, or brain tumors), or learning disabilities.

Inclusion Criteria: * Age 10-17, diagnosis of atopic and/or exercise-induced asthma, referred to physiotherapy. Exclusion Criteria: * Completely symptom-free patients, not understanding Swedish language

Inclusion Criteria: * Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. * Subject is willing and able to comply with study procedures based on the judgement of the investigator. * Age ≥ 18 years of age at the time of consent * ECOG Performance Status of 0-2 (see APPENDIX A: ECOG Performance Status Scale). * Patients must fulfill all eligibility criteria outlined in the LCCC2521 Parent Protocol and consented to LCCC2521 Parent Protocol Exclusion Criteria: * Inaccessible metastatic lesion to research biopsy * Subject has already initiated 2nd line therapy * Concurrent disease or condition that in the opinion of the treating oncologist renders the patient inappropriate for study participation

Inclusion Criteria: * Neonates who are inpatient at the Birmingham Women's Hospital * Confirmed diagnosis of acute pulmonary hypertension, congenital diaphragmatic hernia, hypoxic ischaemic encephalopathy, or bronchopulmonary dysplasia/chronic lung disease (defined by oxygen/respiratory support requirement at 36 weeks post menstrual/corrected gestational age). OR * Health control (\>36 weeks - well and on the postnatal ward) * Well preterm neonate (\<36 weeks) admitted to the NICU, transitional care or post-natal wards. * Informed consent obtained from parent(s) or legal guardian(s) Exclusion Criteria: * Presence of major congenital heart disease (other than patent foramen ovale or patent ductus arteriosus). * Presence of other life-limiting congenital anomalies (other than CDH) or syndromes that could independently affect cardiac function. * Inability to obtain adequate echocardiographic images for STE analysis after reasonable attempts. * If the neonatal consultant or neonatal nurse caring for the neonate feels that the neonate is too unstable for inclusion in the study or that consent should not be sought from parents.

Inclusion Criteria: 1. Patients aged 18-70 years (inclusive), regardless of gender. 2. Diagnosis \& Treatment Plan: Histopathologically confirmed early-stage or advanced breast cancer patients eligible for AC regimen (liposomal doxorubicin + cyclophosphamide) chemotherapy per clinical guidelines. 3. ECOG Performance Status: Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1. 4. Anticipated survival ≥3 months. 5. Organ Function Requirements: Hematologic: Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L ,Platelet count ≥75 × 10⁹/L Hemoglobin ≥90 g/L Hepatic: Non-liver metastasis: Total bilirubin (TBIL) ≤1.5 × upper limit of normal (ULN) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN Liver metastasis: TBIL ≤1.5 × ULN ,ALT and AST ≤5 × ULN Renal: Serum creatinine (Cr) ≤1.5 × ULN or creatinine clearance (Ccr) ≥50 mL/min Coagulation: International normalized ratio (INR) or prothrombin time (PT) ≤1.5 × ULN Activated partial thromboplastin time (APTT) ≤1.5 × ULN 6. Contraception: Female patients: Must use effective contraception (e.g., intrauterine device \[IUD\], oral contraceptives, or condoms) during the study and for 6 months after study completion. A negative serum pregnancy test within 7 days prior to enrollment is required, and patients must be non-lactating. Male patients: Must agree to use contraception during the study and for 6 months after study completion. 7. Informed Consent: Patients must voluntarily participate, provide signed informed consent, and comply with protocol-specified procedures (blood tests, follow-ups, etc.). Exclusion Criteria: 1. Received chemotherapy, radiotherapy, biologics, targeted therapy, immunotherapy, or other antitumor treatments within 4 weeks before the first study dose (or within 5 half-lives, whichever is shorter). Exceptions: The washout period may be adjusted per investigator judgment (e.g., shortened to 2 weeks for endocrine therapy to avoid prolonged patient waiting). 2. Previous treatment with liposomal doxorubicin or similar formulations. 3. Allergy History: Known hypersensitivity to liposomal products or doxorubicin. 4. Cardiovascular Diseases: Severe arrhythmias/conduction abnormalities (e.g., clinically significant ventricular arrhythmias, second- or third-degree AV block). History of myocardial infarction, coronary artery bypass grafting (CABG), or heart failure (NYHA Class ≥II). LVEF ≤50%or prolonged QTcF (\>450 ms in males; \>470 ms in females). 5. Active Infections: Grade ≥2 （NCI CTCAE v5.0） 6. Immunosuppression: Active autoimmune diseases, immunodeficiency (e.g., HIV-positive), or congenital/acquired immune disorders. History of organ transplantation or chronic corticosteroid use. 7. HBsAg-positive with HBV-DNA ≥500 IU/mL. Exception: If HBV-DNA \<500 IU/mL and chronic hepatitis is deemed stable/inactive by the investigator, enrollment is permitted. 8. Other Infections: Positive for HCV antibody or syphilis-specific antibody. 9. Neurological/Psychiatric Disorders: History of epilepsy, dementia, or other uncontrolled conditions. 10. CNS Metastases: Symptomatic brain or leptomeningeal metastases, or uncontrolled CNS lesions. Exception: Asymptomatic brain metastases or lesions stable for ≥28 days without steroids/antitumor therapy are allowed. 11. Any other condition that, per investigator assessment, may compromise patient safety or study compliance. 12. Pregnant or breastfeeding women. 13. Patients deemed ineligible for the study by the investigator.

Inclusion Criteria: * age ≥60 years * ability to communicate and complete the questionnaires in Indonesian * had lived in the nursing home for at least 3 months, * had a Mini-Mental State Examination score of ≥25, had self-reported PSQI Indonesian version scores of ≥5 (where higher scores indicate worse sleep) over the past 4 weeks, * agreed to participate in the research Exclusion Criteria: * The exclusion criteria in this study were severe psychiatric disorders, such as schizophrenia, bipolar disorder, or current receipt of intensive psychiatric treatment.

Inclusion Criteria: * Documented diagnosis of WHO PAH Group 1 in any of the following subtypes: * Idiopathic PAH * Heritable PAH * Drug/toxin-induced PAH * PAH associated with connective tissue disease (CTD) * PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following repair * Men and women 18 and 75 years of age (inclusive) * Must have a body mass index (BMI) of ≥18.5 kg/m\^2 and ≤35.0 kg/m\^2 at screening. * Baseline RHC performed during the Screening Period documenting a PVR of ≥ 400 dyn/sec/cm\^5 ; pulmonary capillary wedge pressure (PCWP) ≤15 mmHg and mean pulmonary artery pressure (mPAP) \>20 mmHg. PVR enrichment criteria to ensure population baseline PVR \>700 dynes/sec/cm\^5 * On stable doses of background PAH therapy including endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclins, and soluble guanylate cyclase stimulators for ≥90 days prior to screening. Current use of sotatercept is not permitted. * 6MWD ≥ 100 and ≤ 475 m Exclusion Criteria: * Diagnosis of PAH WHO Groups 2, 3, 4, or 5. * Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis-associated PAH, and pulmonary veno-occlusive disease. * Any of the following blood pressure-related values or abnormalities: Uncontrolled systemic hypertension as evidenced by sitting systolic BP \>160 mmHg or sitting diastolic BP \>100 mmHg at screening, Baseline systolic BP \<90 mmHg at screening, Syncope within 3 months prior to screening * History of restrictive, constrictive, or congestive cardiomyopathy. * ECG with Fridericia's corrected QT interval (QTcF) ≥ 450 msec in males or ≥ 470 msec in females at screening or ≥500 msec in the presence of a right bundle branch block. * Personal or family history of long QT syndrome or sudden cardiac death. * Presence of a CardioMEMS device or any other implanted hemodynamic monitoring device. * Forced vital capacity (FVC) \<70 percent on pulmonary function test (PFT) performed no more than 6 months prior to screening; or if FVC is 60 percent to 69 percent, must have a chest computed tomography scan within 12 months with no more than mild interstitial lung disease. * History of atrial fibrillation or atrial flutter. * History of cerebrovascular accident, intracranial hemorrhage, or subdural hematoma at anytime, or a fall associated with head trauma within 3 months of screening. * Acutely decompensated right heart failure within 30 days prior to screening, as per investigator assessment. * Clinically significant ischemic, valvular, constrictive heart disease, or heart failure with preserved ejection fraction in the opinion of the investigator. * History of pneumonectomy. * Untreated or inadequately treated (in the opinion of the investigator) obstructive sleep apnea. * Acute or chronic hepatitis B or C infection, defined as: * Hepatitis B virus: a positive hepatitis B surface antigen test or a positive hepatitis B core antibody test with detectable DNA * Hepatitis C virus (HCV): a positive hepatitis C antibody test with detectable HCV ribonucleic acid (RNA).Participants with a positive hepatitis C antibody test, but no detectable HCV RNA who completed treatment with direct-acting antivirals may be considered after discussion with the medical monitor. * History of or currently diagnosed with a bleeding disorder, including but not limited to hemophilia, von Willebrand disease, thrombocytopenia, or significant bleeding history defined as any bleeding event requiring medical intervention. * Received treatment with any of the following excluded medications: * Currently receiving strong cytochrome P450 (CYP) 3A inducers or CYP3A inhibitors (except for topical administration) * Currently receiving or anticipated need to receive any anticoagulant (e.g., heparins, vitamin K antagonists, direct oral anticoagulants, or direct thrombin inhibitors). * Current use of sotatercept. Note: participants who previously received sotatercept may be considered if the last dose administered was \>6 months prior to screening, participant had no significant bleeding events while on sotatercept. * Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to screening or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible). * History of atrial septostomy within 180 days prior to screening. * Current participation in another investigational clinical trial and/or receipt of any investigational medication within 90 days prior to screening. * Previous randomization into this or another IKT-001 study. * Any social, behavioral, or medical reason that would preclude completion of the study, in the judgement of the investigator. * Currently lactating, pregnant or planning on becoming pregnant during the study. * Prior receipt of a solid organ transplant or stem cell transplant. * Planned surgery that would require any study drug interruption or interfere with study assessments during the study (minor procedures may be allowed in consultation with the medical monitor). * Malignancy within the last 5 years prior to consent except completely treated non-metastatic-basal cell, squamous cell, in situ cervical cancer, and clinically localized National Comprehensive Cancer Network very low to low risk prostate cancer under active surveillance.

Inclusion Criteria: * Age ≥18 years * Histologically or cytologically confirmed locally advanced or metastatic HR-positive, HER2-negative breast cancer * HR-positive defined as ER and/or PR ≥1% by IHC * HER2-negative per ASCO/CAP guidelines * At least one measurable extracranial lesion per RECIST v1.1 * ECOG performance status 0-1 * Prior progression on CDK4/6 inhibitor plus endocrine therapy * Adequate organ and cardiac function * Postmenopausal women, or premenopausal women receiving ovarian function suppression Exclusion Criteria: * Active or untreated CNS metastases * Prior treatment with ADCs containing topoisomerase I inhibitor payloads * Active interstitial lung disease or pneumonitis * Uncontrolled cardiovascular disease or active infection * Prior malignancy within 5 years (with specific exceptions) * Pregnancy or breastfeeding

Inclusion Criteria: * Patients with hormone condition aged 18 years or older and English speaking * Initiating or receiving hormone care in Michigan * Report mild depression or anxiety symptoms, as determined by: 1. A Patient Health Questionnaire (PHQ9) score ≥ 5 AND/OR 2. A Generalized Anxiety Disorder (GAD) score ≥ 5. * Interest or willingness to participate in peer support group meetings either in-person or virtually Exclusion Criteria: * Unable to provide informed consent for any reason * Not fluent in English * Determination by patient's attending healthcare provider that peer mentorship is not appropriate due to unstable psychosis, cognitive disorder, or severe personality disorder, or other issue * At imminent risk of suicide, as determined by active suicide ideation with intent and/or a specific plan (endorsed Columbia Suicide Severity Rating Scale number 4 or number 5 in the past month, number 6 in the past 3 months, or spontaneous report) * Already receiving or intending to receive formalized individual peer specialist services through another community mental health program or organization * Residing outside of the state of Michigan, or planning to move out of the state of Michigan in the next 6 months

Inclusion Criteria: * Meets the criteria of either the "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke" or the "Chinese Guidelines for the Diagnosis and Treatment of Acute Cerebral Hemorrhage" and is confirmed by CT or MRI; * Patients with stable vital signs and conditions; * Meets the "Third Edition of the Classification and Diagnosis Criteria for Mental Disorders in China" and has a score of ≥5 on the 9-item Patient Health Questionnaire (PHQ-9) scale; * Patients are over 18 years old; * Can understand the relevant content of the scale correctly and provide answers independently or with the help of others, have clear consciousness and sign the consent form; * Can use smartphones. Exclusion Criteria: * Those with severe functional impairments of important organs such as the heart, lungs, liver and kidneys; * Those without a smart phone;

Inclusion Criteria: * Aged 18-years-old and above * Diagnosed with pulmonary hypertension (group I and non-operable group IV) by right heart catheterisation showing: * a baseline mean pulmonary artery pressure \>20mmHg * pulmonary vascular resistance \>2 Wood Units * pulmonary capillary wedge pressure \<15mmHg * Able to provide written informed consent Exclusion Criteria: * Diagnosis with pulmonary hypertension of any other cause * Group II (PH due to left heart disease) * Group III (PH due to hypoxic lung disease) * Operable group IV (PH due to chronic thromboembolic disease amenable to surgical treatment) * Group V (unclear and/or multifactorial elements). * Planned treatment with a research trial medication during the study timeframe * Consenting clinician and/or patient concern regarding the patient's safety in performing a home-based exercise programme * Patients with syncopal episodes felt to be related to pulmonary hypertension at time of exercise intervention initiation. * Severe concurrent medical condition that would prevent participation in study procedures * Life expectancy \<3 months

Inclusion Criteria: * Patients who are persistent allergic asthma. * Patients who meet the diagnostic criteria for the spleen deficiency and dampness accumulation syndrome. * Patients who are aged between 18 and 80 years. * Patients who voluntarily accept the treatment and sign the informed consent form. Exclusion Criteria: * Patients who have chronic obstructive pulmonary disease, interstitial lung disease, bronchiectasis, allergic bronchopulmonary aspergillosis, eosinophilic granulomatosis with polyangiitis , active pulmonary tuberculosis, or pulmonary embolism, etc. * Patients who have severe cardiovascular or cerebrovascular diseases. * Patients who have severe liver or kidney diseases. * Patients who have a history of tumor. * Patients who have cognitive impairment or psychiatric disorders. * Patients who are pregnant or breastfeeding. * Patients who are allergic to medication(s) used. * Patients who participated in another clinical trial within one month prior to enrollment.

Inclusion Criteria for Providers: 1. Currently work for UC San Diego Health, with a primary appointment in one of the eight primary care clinics 2. Conduct ambulatory care visits for blood pressure management with at least 20 patients with a diagnosis of pre- or stage 1 hypertension Inclusion Criteria for Patients: 1. Have received a diagnosis of pre- or stage 1 hypertension, and/or having SBP 120-139, DBP \<89 2. be receiving care from one of the enrolled providers 3. be currently engaging in \<150 minutes/week of at least moderate intensity exercise (see below) 4. be between age 18 and 80 years 5. not currently taking anti-hypertensive medication 6. able to read, speak, and understand English. Exclusion Criteria for Providers: 1. planning to leave UCSD Health in the next 18 months 2. participated in the co-design workshops to design the PACE system 3. being unwilling to be randomized to one of the three conditions. Exclusion Criteria for Patients: 1. any condition that would contraindicate unsupervised exercise as determined by their provider, such as severe cardiovascular or pulmonary disease limiting exercise tolerance 2. plans to change healthcare providers within the next two months 3. planned surgery or procedure that could impact mobility within the next five months 4. pregnancy.

Inclusion Criteria: patients diagnosed according to the 1999 WHO diagnostic criteria for T2DM with a duration of less than 5 years HbA1c levels between 6.5% and 10% no history of insulin therapy age between 20 and 70 years. Exclusion Criteria： acute complications of diabetes, such as diabetic ketoacidosis severe acute or chronic conditions affecting the liver, kidneys, heart, cerebrovascular system, gastrointestinal tract, or acute infectious diseases pregnancy or plans for pregnancy soon allergies to quinoa or bean products participation in other dietary interventions or drug clinical trials within the past three months gastrointestinal diseases within two weeks prior to enrolment.

Inclusion Criteria: * Adults aged 19 to 80 years at the time of informed consent * Adults with type 2 diabetes not using insulin * Patients treated with GLP-1 agonist, oral hypoglycemic agents, and/or lifestyle modifications * Patients who have maintained stable diabetes treatment for at least 3 months without changes * HbA1c between 7.5% and 10.0% * Willing to wear personal continuous glucose monitoring device (CGM) * Willing to install and use CGM-linked app on personal smartphone with continuous access to WIFI or cellular data * Able to read and write Korean as judged by investigator * Willing to use medically acceptable contraception until end of study (sterile status, intrauterine device, or concurrent use of male/female barrier method with spermicide) * Fully informed about the clinical trial and voluntarily consenting to participate Exclusion Criteria: * Type 1 diabetes mellitus * Gestational diabetes mellitus * History of pancreatectomy * Continuous or intermittent insulin therapy for 7 days or more within 3 months * Oral or IV steroid treatment within 1 month prior to informed consent * Serious infection, surgery (scheduled or history), or severe trauma within 3 months prior to informed consent * History of malignancy within 1 year prior to informed consent (except thyroid cancer) * On hemodialysis or peritoneal dialysis or eGFR \< 30 mL/min/1.73m2 * Unable to avoid the following concomitant medications, devices, or treatments during the study: CGM other than study device, X-ray/MRI/CT scans, radiofrequency thermal therapy, implantable devices such as pacemakers, immunosuppressants, steroids, IV vitamin preparations, cancer treatment, hemodialysis/peritoneal dialysis, insulin therapy * Uncontrolled thyroid disease or clinically significant severe endocrine disorders (Cushing's syndrome, pheochromocytoma, etc.) * Severe allergic reaction to skin adhesives (e.g., dyspnea, severe rash, edema) * Whole blood donation within 60 days, apheresis within 30 days, or blood transfusion within 90 days prior to device application * Judged by investigator as unable to handle continuous glucose monitoring device * Pregnant or lactating women * Planning pregnancy within 1 year * Otherwise judged by investigator as inappropriate for participation in this clinical trial